would
best
empir
therapi
patient
ceftriaxon
azithromycin
linezolid
addit
concern
meliodosi
patient
start
ceftazidim
azithromycin
vancomycin
develop
progress
hypoxemia
agit
time
intub
start
mechan
ventil
bronchoscop
bronchoalveolar
lavag
bal
right
lower
lobe
reveal
wbc
neutrophil
sampl
rapidli
progress
pleural
effus
show
pleural
fluid
ph
glucos
mgdl
ldh
iul
gram
stain
fluid
reveal
cluster
gram
posit
cocci
chest
tube
drainag
right
pleural
space
perform
urinari
antigen
test
streptocococcu
pneumonia
fungal
serolog
neg
empir
switch
vancomycin
linezolid
bal
pleural
fluid
cultur
grew
methicillinresist
staphylococcu
aureu
mrsa
serum
immunoglobulin
ig
subsequ
found
low
given
ivig
prolong
icu
cours
ultim
discharg
acut
rehabilit
facil
subsequ
return
full
function
statu
continu
receiv
intermitt
outpati
ivig
patient
admit
icu
sever
communityacquir
pneumonia
cap
gener
fall
one
two
categori
whose
symptom
sever
comorbid
condit
requir
icu
admiss
present
transfer
icu
later
progress
declin
despit
receiv
inpati
therapi
patient
need
mechan
ventil
vasopressor
support
septic
shock
automat
requir
intens
care
howev
decis
admit
icu
difficult
obviou
need
present
earli
identif
patient
like
deterior
import
increas
mortal
associ
icu
transfer
delay
respiratori
failur
onset
septic
shock
pool
analysi
four
prospect
cap
studi
delayedtransf
compar
direct
emerg
depart
ed
icu
admiss
demonstr
delayedtransf
group
higher
mortal
vs
p
hospit
length
stay
day
vs
day
p
propensitymatch
analysi
delay
transfer
icu
repres
progress
pneumonia
despit
appropri
treatment
mani
patient
subtl
clinic
find
upon
present
predict
aggress
approach
lead
improv
outcom
use
presenc
idsaat
minor
criteria
tabl
ed
beforeaft
qualiti
improv
project
demonstr
decreas
mortal
adjust
odd
ratio
confid
interv
ci
p
fewer
delay
icu
transfer
vs
p
minim
increas
direct
admiss
icu
aggress
preicu
assess
resuscit
protocol
util
pneumonia
sever
index
psi
score
use
predict
mortal
need
hospit
admiss
limit
abil
predict
need
intens
respiratori
monitor
vasopressor
support
initi
addit
idsaat
minor
criteria
sever
score
smartcop
gener
good
sensit
threshold
set
optim
howev
score
tool
lead
signific
increas
icu
admiss
follow
rigor
requir
prospect
valid
aggress
diagnost
test
use
sever
cap
requir
icu
admiss
risk
factor
healthcareassoci
pneumonia
hcap
patient
probabl
find
pathogen
resist
usual
cap
empir
therapi
eg
staphylococcu
aureu
pseudomona
aeruginosa
increas
identif
specif
pathogen
lead
tailor
antimicrobi
thu
decreas
cost
exposur
unnecessari
medic
patient
invas
ventil
direct
access
lower
respiratori
tract
provid
opportun
perform
endotrach
aspir
bronchoalveolar
lavag
bal
moreov
bronchoscop
bal
use
sputum
blood
cultur
yield
pathogen
prospect
studi
patient
admit
cap
fiberopt
bronchoscop
bal
provid
addit
diagnost
valu
patient
could
expector
sputum
treatment
failur
h
admiss
blood
sputum
cultur
gener
low
sensit
still
perform
upon
transfer
icu
even
nonintub
patient
growth
inhibit
antibiot
decreas
diagnost
yield
test
less
aureu
gramneg
bacilli
predomin
pathogen
pleural
fluid
sampl
necessari
cap
patient
larg
pleural
effus
either
upon
admiss
one
develop
empir
treatment
cap
complic
pleural
space
requir
adequ
drainag
urinari
antigen
test
reason
sensit
excel
specif
detect
streptococcu
pneumonia
legionella
pneumophila
serogroup
test
stay
posit
day
patient
pneumonia
week
l
pneumophila
although
antibiot
sensit
data
obtain
test
qualit
import
verifi
antibiot
regimen
adequ
cover
pathogen
viral
test
import
especi
appropri
season
posit
influenza
test
criticallyil
patient
impetu
antivir
therapi
hasten
diseas
resolut
decreas
spread
microorgan
respons
cap
icu
mirror
outpati
set
addit
gramneg
pathogen
mrsa
review
studi
patient
cap
admit
icu
show
common
typic
bacteri
pathogen
pneumonia
l
pneumophila
haemophilu
influenza
aerob
gramneg
bacilli
aureu
rel
frequenc
atyp
pathogen
icu
set
unclear
heterogen
diagnost
techniqu
approxim
respiratori
virus
either
pure
coinfect
detect
sever
pneumonia
common
culprit
includ
parainfluenza
viru
human
metapneumoviru
influenza
b
respiratori
syncyti
viru
adenoviru
much
less
common
viral
pathogen
includ
coronavirus
sar
viru
middl
east
respiratori
syndrom
coronaviru
merscov
parechovirus
enterovirus
epidemiolog
risk
factor
help
suggest
less
common
etiolog
tabl
structur
lung
diseas
eg
copd
repeat
exacerb
bronchiectasi
prior
hospit
healthcar
exposur
pose
increas
risk
pseudomona
chronic
alcohol
risk
gramneg
pathogen
klebsiella
pneumonia
acinetobact
speci
endstag
renal
diseas
inject
drug
use
prior
influenza
infect
prior
treatment
fluoroquinolon
pose
increas
risk
aureu
sever
cap
time
diagnosi
adequ
empir
antimicrobi
therapi
paramount
retrospect
analysi
adult
patient
septic
shock
major
pulmonari
primari
site
infect
demonstr
hour
delay
initi
appropri
antibiot
therapi
onset
hypotens
associ
mean
decreas
surviv
consider
need
alter
empir
regimen
cover
specif
perhap
drugresist
organ
major
consider
patient
transfer
icu
alreadi
standard
empir
antimicrobi
coverag
cap
absenc
risk
factor
hcap
drugresist
pathogen
adequ
coverag
pneumonia
l
pneumophila
crucial
combin
antibiot
betalactam
cefotaxim
ceftriaxon
ampicillinsulbactam
either
macrolid
fluoroquinolon
recommend
recent
prospect
random
trial
demonstr
improv
clinic
outcom
combin
therapi
compar
betalactam
monotherapi
confirm
multipl
observ
studi
show
better
clinic
outcom
decreas
mortal
combin
therapi
especi
bacterem
pneumococc
pneumonia
suspect
pseudomona
cap
dual
therapi
requir
take
form
one
three
initi
combin
antipneumococc
antipseudomona
betalactam
piperacillintazobactam
cefepim
imipenem
meropenem
plu
fluoroquinolon
ciprofloxacin
levofloxacin
orbetalactam
plu
aminoglycosid
azithromycin
orbetalactam
plu
aminoglycosid
antipneumococc
fluoroquinolon
mrsa
pneumonia
linezolid
superior
vancomycin
particularli
toxinsecret
communityacquir
strain
culprit
random
doubleblind
trial
compar
linezolid
doseadjust
vancomycin
treatment
mrsaproven
hap
hcap
demonstr
erad
mrsa
clinic
cure
statist
better
linezolid
linezolid
less
incid
nephrotox
set
methicillinsuscept
aureu
betalactam
therapi
still
treatment
choic
presenc
caprel
pleural
effus
thoracentesi
distinguish
uncompl
parapneumon
effus
upp
complic
parapneumon
effus
cppe
empyema
frank
pu
posit
pleural
fluid
gram
stain
cultur
indic
infect
pleural
space
need
immedi
drainag
howev
pleural
fluid
gram
stain
cultur
neg
cppe
empyema
situat
pleural
fluid
chemistri
effici
way
assess
effus
metaanalysi
show
pleural
fluid
ph
highest
diagnost
accuraci
detect
complic
effus
follow
glucos
lactat
dehydrogenas
ldh
optim
threshold
still
matter
debat
ph
glucos
mgdl
andor
ldh
level
iul
suggest
cppe
empyema
necess
pleural
drainag
achiev
good
outcom
pleural
space
evacu
cppe
fibrin
adhes
develop
neutrophil
bacteria
accumul
lead
empyema
optim
therapi
cppe
empyema
hing
adequ
antibiot
coverag
pleural
drainag
pleural
locul
develop
multipl
thoracostomi
tube
may
need
along
intrapleur
instil
fibrinolyt
agent
random
control
trial
intrapleur
dnase
concomit
tissu
plasminogen
activ
tpa
patient
empyema
show
lower
rate
surgic
referr
hospit
length
stay
compar
placebo
individu
agent
alon
lysi
adhes
decort
via
videoassist
thoracoscop
surgeri
vat
thoracotomi
may
necessari
less
invas
measur
fail
time
surgic
referr
type
surgic
maneuv
though
larg
depend
patient
sever
ill
contrast
uncompl
parapneumon
effus
usual
exud
pleural
fluid
ph
normal
glucos
effus
reactiv
resolv
continu
antibiot
therapi
empir
antibiot
therapi
sever
cap
hing
risk
drug
resist
organ
last
decad
hcap
use
describ
entiti
wherein
patient
develop
pneumonia
outsid
hospit
yet
pathogen
usual
associ
hap
vap
mdr
gramneg
bacilli
mrsa
criteria
hcap
result
number
patient
get
broadspectrum
empir
therapi
remain
subject
debat
use
risk
factor
drugresist
pathogen
drp
lead
antibiot
overtreat
ignor
risk
factor
associ
undertreat
advers
outcom
prospect
observ
studi
shindo
et
al
found
six
independ
risk
factor
pathogen
resist
usual
cap
antibiot
hospit
day
previou
day
antibiot
use
previou
day
nonambulatori
statu
tube
feed
immunocompromis
statu
use
gastric
acid
suppress
medic
presenc
three
risk
factor
prompt
physician
consid
broadspectrum
antibiot
therapi
frequenc
drug
resist
pathogen
may
high
criteria
work
equal
well
previou
definit
hcap
strategi
initi
antibiot
select
base
risk
factor
may
result
far
less
empir
broadspectrum
therapi
still
identifi
major
need
communityacquir
mrsa
camrsa
clone
distinct
usual
caus
hcap
hap
vap
emerg
caus
pneumonia
strike
necrot
featur
methicillin
resist
result
differ
staphylococc
cassett
chromosom
type
sccmec
type
iv
also
includ
gene
encod
pantonvalentin
leukocidin
pvl
exotoxin
presenc
pvl
may
explain
associ
neutropenia
exotoxin
alphahemolysin
may
result
characterist
sever
pulmonari
hemorrhag
mrsa
mssa
infect
antibiot
therapi
also
suppress
toxin
product
provid
better
outcom
improv
surviv
illustr
retrospect
studi
pvlposit
cap
clindamycin
linezolid
shown
suppress
invitro
format
pvl
alphahemolysin
toxic
shock
syndrom
toxin
wherea
vancomycin
betalactam
effect
benefit
clindamycin
combin
betalactam
mssa
cap
unclear
recent
prospect
analysi
demonstr
nearli
camrsa
isol
clindamycin
resist
whether
antibiot
growth
inhibit
detect
micsuscept
test
correl
toxinsuppress
activ
though
unclear
prefer
treatment
pvlposit
mssa
cap
still
unclear
linezolid
appear
reason
choic
camrsa
cap
light
potenti
suppress
exotoxin
offer
faster
erad
mrsa
clone
rapid
bactericid
activ
ceftarolin
cephalosporin
mrsa
activ
may
obviat
need
suppress
exotoxin
product
data
still
limit
procalcitonin
pct
peptid
releas
respons
bacteri
infect
suppress
interferon
induc
viral
infect
potenti
distinguish
bacteri
viral
caus
pneumonia
potenti
guid
antibiot
decis
prospect
studi
cap
clinician
encourag
pct
level
mcgl
discourag
pct
level
mcgl
use
antibiot
base
procalcitonin
cutoff
pct
guidanc
reduc
total
antibiot
exposur
antibiot
prescript
admiss
antibiot
treatment
durat
without
advers
affect
clinic
outcom
analysi
shown
persist
elev
pct
level
associ
advers
outcom
develop
pneumonia
complic
death
similar
benefit
shorten
antibiot
durat
pctdriven
protocol
found
sever
studi
sever
sepsi
despit
studi
pct
fda
approv
indic
us
death
cap
may
result
either
failur
erad
microorgan
inappropri
perhap
exagger
host
respons
infect
led
investig
attempt
modul
inflammatori
respons
sever
cap
corticosteroid
small
prospect
studi
sever
retrospect
studi
support
corticosteroid
administr
sever
cap
larger
random
doubleblind
trial
evalu
efficaci
prednisolon
placebo
patient
sever
cap
psi
iv
v
fail
show
benefici
effect
corticosteroid
convers
highli
select
group
patient
high
creactiv
protein
level
admiss
use
corticosteroid
associ
less
treatment
failur
